Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – November 30, 2019
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol :
View HTML
Toggle Summary ERYTECH Announces Publication of its Phase 2b Trial of Eryaspase in Metastatic Pancreatic Cancer in the European Journal of Cancer
First asparaginase-based therapy to demonstrate clinical efficacy and safety in solid tumors LYON, France and CAMBRIDGE, Mass. , Nov. 25, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma  (Nasdaq and Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
Toggle Summary ERYTECH to Present at Jefferies 2019 Healthcare Conference in London
LYON, France and Cambridge, Mass. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Gil Beyen , Chief
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2019
Conference call and webcast on Friday, November 8 at 2:30 pm CET/8:30 am ET TRYbeCA1, Phase 3 trial of eryaspase in second line pancreatic cancer: positive safety review by independent data monitoring committee opened for patient enrollment in the United States first U.S.
View HTML
More >>

Upcoming Events

There are currently no events to display.

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top